Login / Signup

The combination treatment regimen of ruxolitinib with low-dose mercaptopurine or cytarabine in frail patients with blast-phase myelofibrosis.

Mikhail FominykhVasily ShuvaevIrina MartynkevichLyubov PolushkinaVera UdalevaKudrat Abdulkadyrov
Published in: British journal of haematology (2016)
Keyphrases
  • low dose
  • high dose
  • acute myeloid leukemia
  • combination therapy
  • replacement therapy